AngioDynamics Guides FY26 Revenues Above Estimates

AngioDynamics (ANGO) has initiated its fiscal year 2026 guidance, projecting an adjusted loss of $0.35 to $0.25 per share on net sales between $305 million and $310 million. This anticipated loss range is wider than the average analyst expectation of a $0.23 loss per share, though the sales guidance aligns closely with the $304.86 million consensus. The company also anticipates a $4.0 million to $6.0 million impact from tariffs.

Analysis

AngioDynamics, Inc. (ANGO) has initiated its fiscal year 2026 guidance, presenting a mixed outlook that leans negative on profitability. The company's net sales forecast of $305 million to $310 million is effectively in line with, and at the high end, slightly exceeds the analyst consensus of $304.86 million. However, this modest top-line optimism is overshadowed by a disappointing bottom-line projection. The company's guided adjusted loss of $0.25 to $0.35 per share is significantly wider than the consensus estimate of a $0.23 loss per share. This discrepancy signals that Wall Street's profitability expectations may be too optimistic. AngioDynamics has proactively quantified a specific headwind, anticipating a $4.0 million to $6.0 million negative impact from tariffs, which likely contributes to the weaker earnings outlook and introduces a tangible risk factor for investors to monitor.

Key Decisions for Investors

• Investors should brace for potential downward revisions to analyst earnings estimates for FY2026, as the company's own loss guidance is materially worse than the current consensus.
• The explicitly stated $4 million to $6 million tariff impact should be factored into valuation models as a direct hit to profitability, and the sensitivity of ANGO's margins to trade policy should be considered a key risk.
• While the earnings outlook is a headwind, the in-line to slightly positive revenue guidance suggests underlying business demand is stable; therefore, investors should weigh the near-term margin pressure against the long-term revenue trajectory.